Pharmaceutical Preparations, Except Biologicals: 2006

Issued June 2007

MA325G(06)-1

Current Industrial Reports

Current data are released electronically on Internet for all individual surveys as they become available. Use: http://www.census.gov/mcd/. Individual reports can be accessed by choosing "Current Industrial Reports (CIR)," clicking on "CIRs by Subsector;" then choose the survey of interest. Follow the menu to view the PDF file or to download the worksheet file (XLS format) to your personal computer.

These data are also available on Internet through the U.S. Department of Commerce and STAT-USA by subscription. The Internet address is: www.stat-usa.gov/. Follow the prompts to register. Also, you may call 202-482-1986 or 1-800-STAT-USA, for further information.

SUMMARY OF FINDINGS

The total value of shipments for pharmaceutical preparations in the United States totaled \$127.1 billion in 2006, a 7.2-percent increase from \$118.6 billion in 2005. The leading product category was pharmaceutical preparations acting on the central nervous system and sense organs for human use, which increased 16.5 percent to \$29.9 billion in 2006, from \$25.6 billion in 2005.

The value of shipments for individual product categories in 2006 were: pharmaceutical preparations affecting neoplasm, endocrine

system, and metabolic diseases for human use totaled \$25.6 billion, a 7.6-percent increase from \$23.8 billion in 2005; pharmaceutical preparations acting on the central nervous system and sense organs for human use totaled \$29.9 billion, a 16.5 percent increase from \$25.6 billion in 2005; pharmaceutical preparations acting on the cardiovascular system for human use totaled \$10.9 billion, a 6.5 percent increase from \$10.2 billion in 2005; pharmaceutical preparations acting on the respiratory system for human use totaled \$18.5 billion, a 13.1-percent increase from \$16.4 billion in 2005; pharmaceutical preparations acting on the digestive or genito-urinary system for human use totaled \$15.4 billion, an 8.8-percent decrease from \$16.8 billion in 2005; pharmaceutical preparations acting on the skin for human use totaled \$3.7 billion, virtually unchanged from 2005; vitamin, nutrient, and hematinic preparations for human use totaled \$7.8 billion, a 2.6-percent increase from \$7.6 billion in 2005; pharmaceutical preparations affecting parasitic and infective diseases for human use totaled \$11.7 billion, a 3.8-percent increase from \$11.2 billion in 2005; and pharmaceutical preparations for veterinary use totaled \$3.8 billion, a 12.9-percent increase from \$3.4 billion in 2005.

For general CIR information, explanation of general terms and historical note, see the appendix.

Address inquiries concerning these data to Primary Goods Industries Branch, Manufacturing and Construction Division, (MCD), Washington, DC 20233-6900, or call Michael Reich, 301-763-5163.

For mail or fax copies of this publication, please contact the Information Services Center, MCD, Washington, DC 20233-6900, or call 301-763-4673.

USCENSUSBUREAU

Helping You Make Informed Decisions

U.S. Department of Commerce Economics and Statistics Administration U.S. CENSUS BUREAU

Table 1. Value of Product Class Shipments of Pharmaceutical Preparations, Except Biologicals: 2002 to 2006 [Value in thousands of dollars]

Product code	Product description	2006	2005	2004	2003	2002
	Pharmaceutical preparations	127,141,816	118,647,404	109,851,975	107,561,388	100,741,449
3254121100	Pharmaceutical preparations affecting neoplasms, endocrine system, and metabolic diseases,	25 577 202	22.770.261	20.700.102	20.064.706	17 400 140
3254124100	for human use Pharmaceutical preparations acting on the central nervous system and sense organs, for	25,577,203	23,779,261	20,789,103	20,064,796	17,499,148
3254127100	human use Pharmaceutical preparations acting on the cardiovascular	29,857,767	25,627,446	25,001,154	24,759,304	24,344,732
325412A100	system, for human use Pharmaceutical preparations acting on the respiratory	10,901,093	10,232,377	10,223,797	9,670,724	10,338,754
325412D100	system, for human use Pharmaceutical preparations acting on the digestive or	18,516,268	16,367,218	15,148,446	13,757,675	12,504,287
325412G100	genito-urinary system, for human use Pharmaceutical preparations acting on the skin, for human	15,354,493	16,828,648	15,251,818	15,051,690	13,373,247
325412L100	useVitamin, nutrient, and hematinic preparations,	3,719,087	r/ 3,656,687	3,283,003	3,082,863	2,844,436
325412P100	for human use Pharmaceutical preparations affecting parasitic and	7,754,511	r/ 7,555,845	6,683,224	6,876,680	6,028,849
325412T100	ineffective diseases, for human use Pharmaceutical preparations	11,654,118	11,228,479	10,818,532	11,848,410	11,336,918
	for veterinary use	3,807,276	3,371,443	2,652,898	2,449,246	2,471,078

r/Revised 5 percent or more from previously publised data.

	2006 2005															
Product code	Product description	Total		Pre- scription legend		Non- pre- scription		Bulk ship- ments 1/		Total		Pre- scription legend		Non- pre- scription		Bulk ship- ments 1/
325412	Pharmaceutical preparations (except biologicals)	127,141,816		107,236,274		16,529,983		3,375,559		118,647,404		99,329,466	r/ 1	14,908,998	,	1,408,940
3254121	Pharmaceutical preparations affecting neoplasms, endocrine system, and metabolic diseases,	127,141,010		107,230,274		10,323,363		3,373,333		110,047,404		39,329,400	1/	14,500,550	-	,,100,310
3254121114	for human use Hormones and synthetic substitutes: Corticoids, systemic, local,	25,577,203		(D)		(D)		(D)		23,779,261		(D)		(D)		(D)
3254121121	and topical, including anit- infective combinations	2,040,524 100,089		2,030,818 100,089	b/	9,706 (X)		(D) (D)	b/r/	1,057,296 95,087	a/ b/r/	95,087		8,986 (X)		(D) (D)
3254121126 3254121131	Insulin and antidiabetic		c/	725,844		(X)		- (D)		636,397		636,397		(X)		-
3254121141	agents Oral contraceptive preparationsc/	2,171,265 815,503	c/	2,171,265 815,503		(X) (X)		(D)	r/	1,666,983 753,638	r/	1,666,983 753,638		(X) (X)		(D)
3254121146	Progestogens (excluding premenstrual tension preparations, see															
3254121156	code 325412D196)a/ Thyroid and antithyroid preparations, including iodides	209,130 821,419	a/	209,130 821,419		(X) (X)		(D)	r/ a/	248,791 891,449	r/ a/	248,791 891,449		(X) (X)		(D)
3254121161 3254121165	Anabolic agents Other hormone preparations including sex hormone	29,127		29,127		(X)		-	r/	29,246	r/	29,246		(X)		-
3254121177	combinations, and ACTH Antineoplastic agents, including radioactive isotopes and	989,147		(D)		(D) (X)		(D)	r/	1,005,468	2/	(D)		(D) (X)		(D)
3254121181	specific antineoplastic agents Other pharmaceutical preparations affecting neoplasms, the endocrine	2,709,515		2,709,515		(X)		(D)	a/	3,244,181	a/	3,244,181		(X)		(D)
	system, and metabolic, for human use	13,687,788		(D)		(D)		(D)		12,616,597		(D)		(D)		(D)
3254124	Pharmaceutical preparations acting on the central nervous system and the sense organs, for human															
3254124111	use Parasympathomimetic	29,857,767		26,718,749		2,750,495	b/	388,523		25,627,446		22,238,800		2,249,629	r/ 1	1,139,017
3254124114	cholinergic drugs	25,418 388,940	c/	25,418 (D)		(X) (D)		(D)	c/	16,302 406,069	c/	16,302 (D)		(X) (D)		(D) (D)
3254124117 3254124121	Narcotic: Opium and derivatives	496,534 1,148,759	c/	496,534 1,148,759		(X) (X)		(D)	r/	562,662 1,098,368	r/	562,662 1,098,368		(X) (X)		(D)
3254124122	Salicylates, including aspirin (acetylsalicylic acid) and others such as sodium salicylateb/	387,708		(D)		(D)		(D)	b/	409,547		(D)		(D)		(D)
3254124131 3254124134	Aspirin combinations Acetaminophen and	118,544		(D)		(D)		(D) -	D/	147,857		(D)		(D)		(D) -
3254124137	combinations Antiarthritics (non-	750,750	b/	67,868		682,882	c/	13,544		517,951	b/r/	66,304		451,647		12,717
3254124141	hormonal)	801,094		277,729		523,365	b/	118,450	a/	699,615		319,718		379,897	b/	108,312
3254124144	and suppositories Anticonvulsants, excluding	134,142		(D)		(D)		-		61,673		(D)		(D)		(D)
2254124147	phenobarbital Psycotherapeutic agents:	2,775,639		2,775,639		(X)		24,909	c/	2,095,086		2,095,086		(X)		23,470
3254124147 3254124151	Antidepressants Tranquilizers: Phenothiazine derivatives	6,585,546 114,696		6,585,546 114,696		(X) (X)		29,678	a/	5,320,728 92,407	a/	5,320,728 92,407		(X) (X)		(D)
3254124154 3254124157	Other tranquilizers c/ Other psychotherapeutic	16,023		16,023		(X)		-	r/	32,179	r/	32,179		(X)		-
3254124165	agents	6,600,929		6,600,929		(X)		(D)	r/	5,246,855	r/	5,246,855		(X)		-
	dietaries for weight control)c/ Sedatives and hypnotics: Prescription:	1,445,545	c/	1,445,545		(X)		(D)		1,459,828		1,459,828		(X)		21,479
3254124171 3254124174	Barbituratesb/ Nonbarbituratesb/	18,072 293,755		18,072 293,755		(X) (X)		(D) (D)	r/ b/	16,097 257,029	r/ b/	16,097 257,029		(X) (X)		(D) (D)
3254124178 3254124189	Nonprescription, sleep induc- ers, and calming agents Anesthetics including general, local, and topical (excluding	73,021		(X)		73,021		-		55,100		(X)		55,100		-
	urinary tract anesthetics and skin preparations used as antipruritics)	817,184	a/	801,011		16,173		(D)		720,246		700,276	r/	19,970		(D)
3254124193 3254124196	ials and antiseptics: Contact lens solutions Other eye and ear prepara- tions, including mydriatics,	597,456		-		597,456		(D)		574,614		-		574,614		(D)
3254124197	and miotics Other pharmaceutical prepara- tions acting on the central	1,933,052		(D)		(D)		-		1,708,941		(D)		(D)		(D)
3254127	nervous system and the sense organs for human use Pharmaceutical preparations	3,946,437		3,783,052	b/	163,385	b/	126,062	r/	2,989,275		2,858,014	b/	131,261		(D)
-	acting on the cardiovascular system, for human use	10,901,093		(D)		(D)		115,569		10,232,377		(D)		(D)	r/	121,520

[varae in thouse	ands of donars		200	6				2005	i	
Product code	Product description	Total	Pre- scription legend	Non- pre- scription	Bulk ship- ments 1/		Total	Pre- scription legend	Non- pre- scription	Bulk ship- ments 1/
3254127118	Anticoagulants, hemostatics, and digitalis preparations	1,559,905	(D)	(D)	(D)		1,332,426	(D)	(D)	(D)
3254127128	Hypotensives including rauwolfia- alkaloid preparations and beta receptor blocking agents	(D)	(D)	(D)	(D)		(D)	(D)	(D)	(D)
3254127143 3254127151	Vasodilators: Coronary and peripheral Antiarrythmics, such	(D)	(D)	-	-		(D)	(D)	-	-
3254127156	as propanolol and quinidine	61,049	61,049	(X)	(D)	a/r/	83,716	a/r/ 83,716	(X)	(D)
3254127161	procardia, cardizem, adalata/ Ace inhibitors, such as	624,150	a/ 624,150	(X)	(D)	r/	467,310	r/ 467,310	(X)	(D)
3254127166	vasotec, capoten, prinivil, and zestril Other pharmaceutical prep- arations, acting on the cardiovascular system including vasopressors,	613,090	613,090	(X)	(D)	b/r/	765,193	b/r/ 765,193	(X)	-
2254124	and antiheparin agents for, human use	5,869,439	(D)	(D)	51,648		5,537,159	(D)	(D)	39,203
325412A 325412A113	Pharmaceutical preparations acting on the respiratory system, for human use	18,516,268	16,078,341	2,288,301	c/ 149,626		16,367,218	13,981,182	2,221,232	164,804
	and bronchial dilators, including antiasthmatics Cough and cold preparations (prescription): Cough preparations and expectorants (contain- ing antitussive or other ingredients intended primarily to	8,792,890	(D)	(D)	(D)	r/	8,625,557	(D)	(D)	(D)
325412A123	treat cough only): Narcotic and nonnarcotic Cold preparations containing combinations of the following ingredients, (but not antitussive) nasal decongestant, antihistamine, analgesic, bioflavanoid, or antibiotic):	257,663	257,663	(X)	(D)	r/	208,599	r/ 208,599	(X)	(D)
325412A136	Antihistamine cold preparations	13,058	13,058	(X)	-	b/	17,053	b/ 17,053	(X)	-
325412A143	Other prescription cold prepartations, including nasal									(5)
325412A146	decongestants Cough and cold combina-	(D)	(D)	(X)	-		(D)	(D)	(X)	(D)
325412A153	tions (prescription)a/ Cough and cold preparations (nonprescription): Decongestants, including	61,857	a/ 61,857	(X)	(D)		69,845	69,845	(X)	(D)
	nasal sprays, and nose drops	234,240	(X)	234,240	(D)		237,264	(X)	237,264	(D)
325412A166 325412A171	Cough syrups Capsules and tablets	717,021 716,053	(X) (X)	717,021 716,053	(D)	r/	652,765 673,999	(X) (X)	652,765 r/ 673,999	(D)
325412A176 325412A189	LozengesOther nonprescription cough and cold prepara- tions including topical and	16,129	(X)	16,129	-		18,473	(X)	18,473	-
325412A196	cough dropsOther pharmaceutical prep- arations acting on the respiratory system including beta agonists,	(D)	(X)	(D)	(D)		(D)	(X)	(D)	(D)
325412D	for human use	7,423,621	7,414,511	9,110	(D)	r/	5,571,658	r/ 5,562,437	9,221	(D)
	acting on the digestive or the genito-urinary systems, for human use	15,354,493	13,469,340	1,114,146	c/ 771,007		16,828,648	14,989,165	r/ 1,081,644	757,839
325412D111 325412D115	Digestive system preparations: Enzymes	120,626	a/ 109,261	11,365	(D)		111,041	99,814	11,227	(D)
	classified as analgesics, and antidiarrheals	1,823,760	1,203,674	a/ 620,086	(D)	r/	1,344,512	(D)	(D)	(D)
325412D121	Laxatives: Irritants	101,988	(D)	(D)	(D)		78,469	(D)	(D)	-
325412D123 325412D127	Bulk producing and emollients Fecal softeners	(D) 92,816	(D) (D)	(D) (D)	(D)	a/	(D) 109,128	(D) (D)	(D) (D)	(D)
325412D134 325412D137	Saline	(D) 62,647	(D)	(D) (D)	-		(D) 57,933	(D)	(D) (D)	-
325412D157 325412D168	anticholinergics: Synthetics	4,425	4,425	(X)	-		5,202	5,202	(X)	-
325412D175	agents	1,267,128	(D)	(D)	(D)		1,209,396	1,189,025	a/ 20,371	(D)
	aids containing local anesthetics, for human use	9,340,011	9,327,556	12,455	(D)		11,183,150	11,172,882	r/ 10,268	(D)

Table 2. Value (Value in thousa	of Shipments of Pharmaceutical Preparation ands of dollars]	ns, Except Bio	ologi	cals: 2006 an	nd 20	005										
				200	6							2005				
Product code	Product description			Pre- scription		Non- pre-		Bulk ship-				Pre- scription		Non- pre-		Bulk ship-
couc		Total		legend		scription		ments 1/		Total		legend		scription		ments 1/
325412D177	Genito-urinary preparations: Urinary antibacterials															
325412D182	and antiseptics Diuretics, thiazides and	47,089		(D)		(D)		-		35,748		(D)		(D)		-
	related agents, excluding aminophylline, xan- thine, and rauwolfia-															
	diuretic combinations. (see cardiovascular															
325412D187	preparations)b/ Oxytocicsb/	165,637 98,765	b/	(D) 98,765		(D) (X)		(D)		142,422 89,399		(D) 89,399		(D) (X)		(D)
325412D195 325412D196	Vaginal cleaners Other pharmaceutical prep-	61,544		(D)		(D)		-		67,376		(D)		(D)		-
	arations acting on the genito-urinary system,															
	including urinary tract anesthetics, contraceptive agents, and premenstrual															
	tension preparations, for human use	1,135,319		1,110,613		24,706		(D)		1,362,223		1,338,049	r/	24,174		(D)
325412G	Pharmaceutical preparations	1,100,010		1,110,013		21,700		(2)		1,502,225		1,550,015	-/	21,171		(2)
	acting on the skin, for human use	3,719,087		(D)		2,241,743		(D)	a/r/	3,656,687		(D)	r/	2,063,390		(D)
325412G111	Dermatological preparations: Emollients and protec-															
	tives, including burn remedies and oint-	775,239		35,464		739,775				797,932	c/	27,217		770,715		
325412G116	ment bases Antipruritics and local anesthetic skin	773,239		33,404		739,773				797,932	c/	27,217		770,713		
325412G126	preparationsa/ Antiacne preparations	209,421 554,948		134,012 (D)	b/	75,409 (D)		(D)		183,520 569,426		132,412 342,249		51,108 227,177		(D) (D)
325412G131	Antidandruff and anti- seborrheic prepara-															
2254126122	tions (excluding dan- druff shampoos)	44,036	a/	10,818		33,218		-		33,296		(D)		(D)		-
325412G138	Other dermatological prep- arations including coal tar, sulfur, and resorc-															
325412G141	inol preparations Hemorrhoidal preparations	568,167 76,225		374,592 (D)		193,575 (D)		(D)	r/	704,726 81,192	r/	515,872 (D)		188,854 (D)		(D)
325412G163	External analgesics and counterirritants including					. ,				, ,				. ,		
	ointments, jellies, pastes, creams, cerates, salves,															
325412G166	liquids, and rubbing alcohol Other pharmaceutical prep-	539,860		148,172		391,688		-		476,528	r/	119,558		356,970		-
	arations acting on the skin, for human useb/	880,228	b/	368,901		511,327		(D)	b/r/	739,934	c/	351,656	a/r/	388,278		(D)
325412L	Vitamin, nutrient, and hematinic preparations, for human use a/	7,754,511	a/	1,877,370	a/	5,575,178	b/	301,963	r/	7,555,845	r/	2,099,313	r/	5,190,972	b/	265,560
325412L111	Vitamins: Multivitamins, plain and															
	with minerals, (excluding B complex vitamins	2.076.167	h /	20.202	h /	2.026.974	h /	67.050	w/	2 714 076	h /	27 522	w/	2 677 442	h /	65.843
325412L116	and fish liver oils)b/ Pediatric vitamin prep- arations (drops,	3,076,167	D/	39,293	D/	3,036,874	b/	67,858	r/	2,714,976	b/	37,533	r/	2,677,443	b/	65,843
	suspensions and chewable tablets)	149,571		(D)		(D)	b/	928	b/	144,197		(D)		(D)	b/r/	1,012
325412L121	Prenatal vitamin preparations	120,534		(D)		(D)		(D)	r/	103,719		(D)		(D)		762
325412L126 325412L135	B complex preparations	279,632		11,222		268,410	b/	4,576		267,232		18,540		248,692	b/	5,288
325412L141	including fluoride preparations	704,160 185,254	b/	46,783 (D)	a/	657,377 (D)	b/ a/	91,205 496	r/	726,924 138,549		41,662 (D)	r/	685,262 (D)	c/ a/	67,745 230
325412L146	Nutrients, excluding thera- peutic dietary foods and	103,231		(D)		(D)	u,	150		130,313		(D)		(D)	u,	230
325412L151	infant formulasb/ Tonics and alterativesc/	302,220 31,486		92,780	b/ c/	209,440 31,486	a/	106,696	r/	322,830 27,380		69,734	r/	253,096 27,380	a/	92,929
325412L158	Hematinics: Oral and parenteral			(5)		(70)		(5)				(T)		(5)		(5)
325412L168	with B12	30,726 64,658		(D) (D)		(D) (D)		(D) (D)	b/	32,153 65,125		(D) (D)		(D) (D)		(D) (D)
325412L179	Other vitamin, nutrient, and hematinic prepara-	01,030		(D)		(D)		(D)		03,123		(D)		(D)		(D)
	tions including hopsital solutions but excluding bio-															
	logicals such as blood plasma, for human use	2,508,140	a/	1,463,398		1,044,742	b/	25,815	r/	2,747,200	r/	1,723,729	r/	1,023,471		28,942
325412P	Pharmaceutical preparations affecting parasitic and infec-															
	tive diseases, for human use Anti-infective agents, ex-	11,654,118		10,040,394		1,489,548		124,176	b/	11,228,479	a/	9,822,350		1,234,312		171,817
	cluding cortcoid anti-infec- tive combinations (see product															
325412P111	code 3254121015): Amebicides and tricho-	27.020		27.020						26.007		36,007				
325412P114	monicidesAnthelmintics Systemic antibiotic prep-	37,828 (D)		37,828 (D)		(D)		-		36,007 1,191		(D)		(D)		-
	arations: Broad and medium spec-															
	trum (single or in combi- nations with other anti-															
325412P117	biotics): Tetracyclines, in-															
	cluding chlortet- racycline and congeners	317,073	c/	317,073		(X)		-		275,024		275,024		(X)		_
325412P121	Cephalosporins, such as cefaman-	,	.,	,		(-2)				-,		, *		(-2)		
	dolenafate and cephalexina/	1,036,043	a/	1,036,043		(X)		(D)		1,204,157		1,204,157		(X)		(D)

 $Table\ 2.\ Value\ of\ Shipments\ of\ Pharmaceutical\ Preparations,\ Except\ Biologicals:\ 2006\ and\ 2005\ [Value\ in\ thousands\ of\ dollars]$

			20	06					2005			
Product code	Product description	Total	Pre scription legen	ı pre	e- ship-		Total		Pre- scription legend		Non- pre- scription	Bulk ship- ments 1/
325412P124	Erythromycins, such as erythromycin ethylsuccinate and erythromycin stearate Penicillins (single): Semisynthetic peni- cillins, such as amoxicillins,	103,282	103,28	2 (>	-		107,862		107,862		(X)	-
325412P127 325412P131 325412P135	and ampicillin: Injectable	(D) (D)	(D				206,645 (D)		206,645 (D)		(X) (X)	-
325412P141	and other forms Other broad and medium spectrum antibiotics, excluding sulfa-antibiotic	(D)	(D) (>	ζ) -		(D)		(D)		(X)	-
325412P144	combinations	621,246	(D) ([-		761,658		(D)		(D)	-
325412P147	with sulfonamidesb/ Other systemic antibiotic preparations, including narrow-spectrum anti- biotics and streptomy-	15,541	b/ 15,54	1 ()	-	r/	13,804	r/	13,804		(X)	-
325412P151 325412P156	cins Topical antibiotic preparations Tuberculostatic agents including isoniazid (iso- nicotinic acid hydrazide), and other antitubercular	(D) 276,582	(D		· · · · · · · · · · · · · · · · · · ·	r/	(D) 367,415		(D) (D)		(X) (D)	-
325412P161 325412P164	preparations	29,518 29,287	b/ 29,51 29,28		(D)	b/r/ a/r/	21,903 36,246	b/r/ a/r/	21,903 36,246		(X)	(D)
325412P167 325412P171	nations) Antifungal preparations Antivirals, systemic, such as zovirax, and	22,800 1,074,170	22,80 932,58			b/	25,074 1,233,812	b/	25,074 1,057,129		(X) 176,683	-
325412P174	retrovir Other anti-infective agents Antibacterials and antiseptics:	5,001,668 404,901	(D (D			b/	4,055,319 (D)		(D) (D)		(D) (D)	78,273 (D)
325412P177 325412P181 325412P184	General	247,382 (D)	(D 10,50				271,969 (D)		(D) 9,828		(D) (D)	7,192 (D)
325412T	human use Pharmaceutical preparations for	367,148	349,42	6 17,72	2 (D)	r/	453,386	r/	435,342		18,044	(D)
325412T111 325412T111	Anthelmintics	3,807,276 90,475 319,834	2,580,24 90,47 288,65	5 ()	() -		3,371,443 60,795 257,698		2,333,697 60,795 215,493	r/	853,624 (X) 42,205	r/ 184,122 (D)
325412T126	Penicillins	38,133	20,83	9 17,29	4 -		39,131		26,947		12,184	-
325412T133 325412T136	Other antibiotics including tetracyclines Antiseptics, wound dress-	949,644	905,37	0 44,27	4 (D)		807,354		743,812		63,542	(D)
325412T163	ings and fungicides Hormones including insulin,	66,368	(D) ([-		80,550		(D)		(D)	(D)
325412T171 325412T176 325412T181 325412T196	ACTH (corticotropin), and other hormone preparations Nitrofurans Nutrients and tonics Parasiticides, external Other pharmaceutical preparations including vitamins, minerals, tranquilizers, ataractics,	178,303 (D) (D) 279,202	(D (D	- (E) b/ 1,32	9 (D)	r/	208,499 (D) (D) 161,601		(D) (D) (D)	r/	(D) (D) 1,377 (D)	(D) (D) (D)
	intravenous solutions, sulfonamides, electrolytes, hemostatics, and hematinics, for veterinary use	1,701,294	990,09	8 711,19	6 (D)		1,563,653		1,065,510	a/r/	498,143	(D)

⁻ Represents zero. D Withheld to avoid disclosing data for individual companies. r/Revised 5 percent or more from previously published data. X Not applicable.

^{1/}Data for "Bulk shipments" are excluded from all horizontal ten-digit product detail totals; however, these data are included in all seven-digit product class and six-digit industry level totals. Since bulk shipments are typically reported by a small number of producers, and often must be suppressed, inclusion of bulk shipments in all horizontal totals would require the suppression of additional detail.

Note: Percent of estimation of each item is indicated as follows: a/10 to 25 percent of this item is estimated. b/25 to 50 percent of this item is estimated. c/Over 50 percent of this item is estimated.

Table 3. Domestic Value of Shipments, Exports, Imports, and Apparent Consumption of Pharmaceutical Preparations, Except Biologicals: 2006 and 2005 [Thousands of dollars]

Product code	Product description	Manu- facturers' shipments (value f.o.b. plant)	Exports of domestic merchan- dise 1/	Percent exports to manu- facturers' shipments	Imports for consump- tion 2/ (value)	Apparent consump- tion 3/ (value)	Percent imports to apparent consumption (value)
	2006						
	Pharmaceutical prepartions	127,141,816	11,109,935	8.7	32,297,852	148,329,733	21.8
3254121100	Pharmaceutical preparations affecting neoplasms, endocrine system, and metabolic diseases, for human use	25,577,203	3,377,630	13.2	5,873,319	28,072,892	20.9
3254124100	Pharmaceutical preparations acting on the central nervous system and sense organs, for human use	29,857,767	2,092,310	7.0	5,349,795	33,115,252	16.2
3254127100	Pharmaceutical preparations acting on the cardiovascular system, for human use	10,901,093	1,752,681	16.1	11,785,087	20,933,499	56.3
325412A100	Pharmaceutical preparations acting on the respiratory system, for human use	18,516,268	608,742	3.3	2,269,224	20,176,750	11.2
325412D100	Pharmaceutical preparations acting on the digestive or genito-urinary system, for human use	15,354,493	250,057	1.6	2,120,339	17,224,775	12.3
325412G100	Pharmaceutical preparations acting on the skin, for human use	3,719,087	85,631	2.3	346,580	3,980,036	8.7
325412L100	Vitamin, nutrient, and hematinic preparations, for human use	7,754,511	336,515	4.3	248,060	7,666,056	3.2
325412P100	Pharmaceutical preparations affecting parasitic and infective diseases, for human use	11,654,118	2,349,545	20.2	3,736,216	13,040,789	28.7
325412T100	Pharmaceutical preparations for veterinary use	3,807,276	256,824	6.7	569,232	4,119,684	13.8
	2005						
	Pharmaceutical prepartions	118,647,404	10,181,450	8.6	27,058,021	135,523,975	20.0
3254121100	Pharmaceutical preparations affecting neoplasms, endocrine system, and metabolic diseases, for human use	23,779,261	2,898,772	12.2	4,986,873	25,867,362	19.3
3254124100	Pharmaceutical preparations acting on the central nervous system and sense organs, for human use	25,627,446	2,217,027	8.7	4,643,207	28,053,626	16.6
3254127100	Pharmaceutical preparations acting on the cardiovascular system, for human use	10,232,377	1,295,231	12.7	8,993,166	17,930,312	50.2
325412A100	Pharmaceutical preparations acting on the respiratory system, for human use	16,367,218	458,486	2.8	1,743,603	17,652,335	9.9
325412D100	Pharmaceutical preparations acting on the digestive or genito-urinary system, for human use	16,828,648	347,823	2.1	2,127,985	18,608,810	11.4
325412G100	Pharmaceutical preparations acting on the skin, for human user/	3,656,687	99,119	2.7	387,204	3,944,772	9.8
325412L100	Vitamin, nutrient, and hematinic preparations, for human user/	7,555,845	343,239	4.5	400,727	7,613,333	5.3
325412P100	Pharmaceutical preparations affecting parasitic and infective diseases, for human use	11,228,479	2,269,143	20.2	3,292,511	12,251,847	26.9
325412T100	Pharmaceutical preparations for veterinary use	3,371,443	252,610	7.5	482,745	3,601,578	13.4
1 /5011800:	Conque Rurous report FM FAF II S Exports						

^{1/}Source: Census Bureau report EM 545, U.S. Exports.

^{2/}Source: Census Bureau report IM 145, U.S. Imports for Consumption.
3/Apparent consumption represents new domestic supply and is derived by substracting exports from the total of manufacturers' shipments plus imports.

Table 4. Comparison of North American Industry Classification (NAICS)-Based Product Codes with Schedule B Export Codes and HTSUSA Import Codes: 2006

Product code	Product description	Export code 1/	Import code 2/
3254121100	Pharmaceutical preparations affecting neoplasms, endocrine system, and metabolic disease	3003.31.0000, 3003.39.0000, 3003.40.0000, 3004.31.0000, 3004.32.0000, 3004.39.0050, 3004.90.9115	3003.31.0000, 3003.39.1000, 3003.39.5000, 3003.40.0000, 3004.31.0000, 3004.32.0000, 3004.39.0050, 3004.90.9115
3254124100	Pharmaceutical preparations acting on central nervous system and sense organs	3004.40.0020, 3004.40.0030, 3004.40.0040, 3004.90.9125, 3004.90.9130, 3004.90.9135, 3004.90.9140	3004.40.0020, 3004.40.0030, 3004.40.0040, 3004.90.9122, 3004.90.9126, 3004.90.9128, 3004.90.9130, 3004.90.9135, 3004.90.9140
3254127100	Pharmaceutical preparations acting on cardiovascular system	3004.40.0010, 3004.90.9120	3004.40.0010, 3004.90.9120
325412A100	Pharmaceutical preparations acting on respiratory system	3004.40.0060, 3004.90.9175, 3004.90.9180, 3004.90.9185	3004.40.0060, 3004.90.9175, 3004.90.9180, 3004.90.9185
325412D100	Pharmaceutical preparations acting on digestive or genitro-urinary system	3004.90.9150, 3004.90.9155, 3004.90.9160, 3004.90.9165, 3004.90.9170, 3006.60.0000	3004.90.9150, 3004.90.9155, 3004.90.9160, 3004.90.9165, 3004.90.9170, 3006.60.0000
325412G100	Pharmaceutical preparations acting on skin	3004.40.0050, 3004.90.9145	3004.40.0050, 3004.90.9145
325412L100	Vitamin, nutrient and hematinic preparations	3004.50.4500, 3004.50.5010, 3004.50.5020, 3004.50.5030, 3004.50.5040	3004.50.1000, 3004.50.2000, 3004.50.3000, 3004.50.4000, 3004.50.5010, 3004.50.5020, 3004.50.5030, 3004.50.5040
325412P100	Pharmaceutical preparations affecting parasitic and infective disease	3003.10.0000, 3003.20.0000, 3004.10.1020, 3004.10.1045, 3004.10.5045, 3004.10.5060, 3004.20.0020, 3004.20.0030, 3004.20.0060, 3004.90.1000, 3004.90.9105, 3004.90.9110	3003.10.0000, 3003.20.0000, 3004.10.1020, 3004.10.1045, 3004.10.5045, 3004.10.5060, 3004.20.0020, 3004.20.0030, 3004.20.0060, 3004.90.1000, 3004.90.9105, 3004.90.9110
325412T100	Pharmaceutical preparations for veterinary use	3004.10.1010, 3004.10.5010, 3004.20.0010, 3004.39.0010, 3004.40.0005, 3004.50.5005, 3004.90.9103	3004.10.1010, 3004.10.5010, 3004.20.0010, 3004.39.0010, 3004.40.0005, 3004.50.5005, 3004.90.9103

1/Source: 2006 edition, Harmonized System-based Schedule B, Statistical Classification of Domestic and Foreign Commodities Exported from the United States.

2/Source: Harmonized tariff Schedule of the United States, Annotated (2006).

Appendix.

General CIR Survey Information, Explanation of General Terms and Historical Note

GENERAL

The CIR program has been providing monthly, quarterly, and annual measures of industrial activity for many years. Since 1904, with its cotton and fats and oils surveys, the CIR program has formed an essential part of an integrated statistical system involving the quinquennial economic census, manufacturing sector, and the annual survey of manufactures. The CIR surveys, however, provide current statistics at a more detailed product level than either of the other two statistical programs.

The primary objective of the CIR program is to produce timely, accurate data on production and shipments of selected products. The data are used to satisfy economic policy needs and for market analysis, forecasting, and decision making in the private sector. The product-level data generated by these surveys are used extensively by individual firms, trade associations, and market analysts in planning or recommending marketing and legislative strategies, particularly if their industry is significantly affected by foreign trade. Although production and shipments information are the two most common data items collected, the CIR program collects other measures also such as inventories, orders, and consumption. These surveys measure manufacturing activity in important commodity areas such as textiles and apparel, chemicals, primary metals, computer and electronic components, industrial equipment, aerospace equipment, and consumer goods.

The CIR program uses a unified data collection, processing, and publication system. The U.S. Census Bureau updates the survey panels for most reports annually and reconciles the estimates to the results of the broader-based annual survey of manufactures and the economic census, manufacturing sector. The manufacturing sector provides a complete list of all producers of the products covered by the CIR program and serves as the primary source for CIR sampling. Where a small number of producers exist, CIR surveys cover all known producers of a product. However, when the number of producers is too large, cutoff and random sampling techniques are used. Surveys are continually reviewed and modified to provide the most up-to-date information on products produced. The CIR program includes a group of mandatory and voluntary surveys. Typically the monthly and quarterly surveys are conducted on a voluntary basis. Those companies that choose not to respond to the voluntary surveys are required to submit a mandatory annual counterpart corresponding to the more frequent survey.

NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS), 1997

The adoption of the North American Industry Classification System (NAICS) in the 1997 Economic Census has had a major impact on the comparability of current and historic data. Approximately half of the industries in the manufacturing sector of NAICS do not have comparable industries in the Standard Industrial Classification (SIC) system that was used in the past.

While most of the change affecting the manufacturing sector was change within the sector, some industries left manufacturing and others came into manufacturing. Prominent among those that left manufacturing are logging and portions of publishing. Prominent among the industries that came into the manufacturing sector are bakeries, candy stores where candy is made on the premises, custom tailors, makers of custom draperies, and tire retreading. The net effect of the classification changes are such that if the 1997 value of shipments data for all manufacturers were tabulated on an SIC basis, it would be approximately 3 percent higher.

Listed below are the NAICS sectors:

- 21 Mining
- 22 Utilities
- 23 Construction
- 31-33 Manufacturing
- 42 Wholesale Trade
- 44-45 Retail Trade
- 48-49 Transportation and Warehousing
- 51 Information
- 52 Finance and Insurance
- 53 Real Estate and Rental and Leasing
- 54 Professional, Scientific, and Technical Services
- 55 Management of Companies and Enterprises
- 56 Administrative and Support and Waste Management and Remediation Services
- 61 Educational Services
- 62 Health Care and Social Assistance
- 71 Arts, Entertainment, and Recreation
- 72 Accommodation and Food Services
- 81 Other Services (except Public Administration)

(Not listed above are the Agriculture, Forestry, Fishing, and Hunting sector (NAICS 11), partially covered by the census of agriculture conducted by the U.S. Department of Agriculture, and the Public Administration sector (NAICS 92), covered by the census of governments conducted by the Census Bureau.)

The 20 NAICS sectors are subdivided into 96 subsectors (three-digit codes), 313 industry groups (four-digit codes), and, as implemented in the United States, 1170 industries (five- and six-digit codes).

FUNDING

The Census Bureau funds most of the surveys. However, a number of surveys are paid for either fully or partially by other Federal Government agencies or private trade associations. A few surveys are mandated, but all are authorized by Title 13 of the United States Code.

RELIABILITY OF DATA

Survey error may result from several sources including the inability to obtain information about all cases in the survey, response errors, definitional difficulties, differences in the interpretation of questions, mistakes in recording or coding the reported data, and other errors of collection, response, coverage, and estimation. These nonsampling errors also occur in complete censuses. Although no direct measurement of the biases due to these nonsampling errors has been obtained, precautionary steps were taken in all phases of the collection, processing, and tabulation of the data in an effort to minimize their influence.

A major source of bias in the published estimates is the imputing of data for nonrespondents, for late reporters, and for data that fail logic edits. Missing figures are imputed based on period-to-period movements shown by reporting firms. A figure is considered to be an impute if the value was not directly reported on the questionnaire, directly derived from other reported items, directly available from supplemental sources, or obtained from the respondent during the analytical review phase. Imputation generally is limited to a maximum of 10 percent for any one data cell. Figures with imputation rates greater than 10 percent are suppressed or footnoted. The imputation rate is not an explicit indicator of the potential error in published figures due to nonresponse, because the actual yearly movements for nonrespondents may or may not closely agree with the imputed movements. The range of difference between the actual and imputed figures is assumed to be small. The degree of uncertainty regarding the accuracy of the published data increases as the percentage of imputation increases. Figures with imputation rates above 10 percent should be used with caution.

DATA REVISIONS

Statistics for previous years may be revised as the result of corrected figures from respondents, late reports for which imputations were originally made, or other corrections. Data that have been revised by more than 5 percent from previously published data are indicated by footnotes.

DISCLOSURE

The Census Bureau collects the CIR data under the authority of Title 13, United States Code, which specifies that the information can only be used for statistical purposes and cannot be published or released in any manner that would identify a person, household, or establishment. "D" indicates that data in the cell have been suppressed to avoid disclosure of information pertaining to individual companies.

EXPLANATION OF GENERAL TERMS

Capacity. The maximum quantity of a product that can be produced in a plant in 1 day if operating for 24 hours. Includes the capacity of idle plants until the plant is reported to be destroyed, dismantled, or abandoned.

Consumption. Materials used in producing or processing a product or otherwise removing the product from the inventory.

Exports. Includes all types of products shipped to foreign countries, or to agents or exporters for reshipment to foreign countries.

Gross shipments. The quantity or value of physical shipments from domestic establishments of all products sold, transferred to other establishments of the same company, or shipped on consignment, whether for domestic or export sale or use. Shipments of products purchased for resale are omitted. Shipments of products made under toll arrangements are included.

Interplant transfers. Shipments to other domestic plants within a company for further assembly, fabrication, or manufacture.

Inventories. The quantity or value of finished goods, work in progress, and materials on hand.

Machinery in place. The number of machines of a particular type in place as of a particular date whether the machinery was used for production, prototype, or sampling, or was idle. Machinery in place includes all machinery set up in operating positions.

Net receipts. Derived by subtracting the materials held at the end of the previous month from the sum of materials used during the current month.

Production. The total volume of products produced, including: products sold; products transferred or added to inventory after adjustments for breakage, shrinkage, and obsolescence, plus any other inventory adjustment; and products that undergo further manufacture at the same establishment.

Quantities produced and consumed. Quantities of each type of product produced by a company for internal consumption within that same company.

Quantity and value of new orders. The sales value of orders received during the current reporting period for products and services to be delivered immediately or at some future date. Also represents the net sales value of contract change documents that increase or decrease the sales value of the orders to which they are related, when the parties concerned are in substantial agreement as to the amount involved. Included as orders are only those that are supported by binding legal documents such as signed contracts or letter contracts.

Quantity and value of shipments. The figures on quantity and value of shipments represent physical shipments of all products sold, transferred to other establishments of the same company, or shipped on consignment, whether for domestic or export sale. The value represents the net sales price, f.o.b. plant, to the customer or branch to which the products are shipped, net of discounts, allowances, freight charges, and

returns. Shipments to a company's own branches are assigned the same value as comparable appropriate allocation of company overhead and profit. Products bought and resold without further manufacture are excluded.

Stocks. Total quantity of ending finished inventory.

Unfilled orders (backlog). Calculated by adding net new orders and subtracting net sales from the backlog at the end of the preceding year.

HISTORICAL NOTE

Data on pharmaceutical preparations, except biologicals, have been collected by the Census Bureau since 1962. Historical data may be obtained from Current Industrial Reports available at your local Federal Depository Library.